Cross-species Genomics (CrossGen) Limited uses its patented CG⁺ technology to develop in silico (computer) tools for the toxicological assessment of drug candidates in the early stages of the drug development process. CrossGen’s proprietary in silico prediction and selection is followed by in vitro and in vivo experimental validation. Our capabilities are based on a broad and continuing growing infrastructure of proprietary scientific understanding which underpins our predictive platforms, algorithms and computational biology tools. CrossGen operates through collaborations and partnerships. However a service agreement may be entered into at client’s request.